Recursion Pharmaceuticals Statistics
Total Valuation
RXRX has a market cap or net worth of $1.65 billion. The enterprise value is $1.33 billion.
| Market Cap | 1.65B |
| Enterprise Value | 1.33B |
Important Dates
The next estimated earnings date is Monday, May 6, 2024, after market close.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RXRX has 215.83 million shares outstanding. The number of shares has increased by 18.41% in one year.
| Shares Outstanding | 215.83M |
| Shares Change (YoY) | +18.41% |
| Shares Change (QoQ) | +3.65% |
| Owned by Insiders (%) | 5.65% |
| Owned by Institutions (%) | 92.43% |
| Float | 188.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 37.50 |
| Forward PS | 30.44 |
| PB Ratio | 3.61 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 29.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.70, with a Debt / Equity ratio of 0.11.
| Current Ratio | 4.70 |
| Quick Ratio | 4.27 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -72.90% and return on invested capital (ROIC) is -68.09%.
| Return on Equity (ROE) | -72.90% |
| Return on Assets (ROA) | -50.90% |
| Return on Capital (ROIC) | -68.09% |
| Revenue Per Employee | $89,150 |
| Profits Per Employee | -$656,132 |
| Employee Count | 500 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.06M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.69% in the last 52 weeks. The beta is 0.75, so RXRX's price volatility has been lower than the market average.
| Beta (1Y) | 0.75 |
| 52-Week Price Change | +21.69% |
| 50-Day Moving Average | 10.78 |
| 200-Day Moving Average | 9.34 |
| Relative Strength Index (RSI) | 30.32 |
| Average Volume (30 Days) | 6,468,712 |
Short Selling Information
The latest short interest is 39.76 million, so 18.42% of the outstanding shares have been sold short.
| Short Interest | 39.76M |
| Short Previous Month | 43.52M |
| Short % of Shares Out | 18.42% |
| Short % of Float | 21.12% |
| Short Ratio (days to cover) | 5.74 |
Income Statement
In the last 12 months, RXRX had revenue of $44.58 million and -$328.07 million in losses. Loss per share was -$1.58.
| Revenue | 44.58M |
| Gross Profit | 1.99M |
| Operating Income | -350.06M |
| Pretax Income | -332.13M |
| Net Income | -328.07M |
| EBITDA | -299.66M |
| EBIT | -332.13M |
| Loss Per Share | -$1.58 |
Balance Sheet
The company has $394.80 million in cash and $50.67 million in debt, giving a net cash position of $344.12 million or $1.59 per share.
| Cash & Cash Equivalents | 394.80M |
| Total Debt | 50.67M |
| Net Cash | 344.12M |
| Net Cash Per Share | $1.59 |
| Equity / Book Value | 463.44M |
| Book Value Per Share | 2.15 |
| Working Capital | 344.97M |
Cash Flow
In the last 12 months, operating cash flow was -$287.78 million and capital expenditures -$11.96 million, giving a free cash flow of -$299.74 million.
| Operating Cash Flow | -287.78M |
| Capital Expenditures | -11.96M |
| Free Cash Flow | -299.74M |
| FCF Per Share | -$1.44 |
Margins
Gross margin is 4.46%, with operating and profit margins of -785.33% and -735.99%.
| Gross Margin | 4.46% |
| Operating Margin | -785.33% |
| Pretax Margin | -745.10% |
| Profit Margin | -735.99% |
| EBITDA Margin | -672.27% |
| EBIT Margin | -745.10% |
| FCF Margin | -672.43% |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.41% |
| Shareholder Yield | -18.41% |
| Earnings Yield | -19.63% |
| FCF Yield | -17.93% |
Analyst Forecast
The average price target for RXRX is $17.40, which is 128.05% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.40 |
| Price Target Difference | 128.05% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RXRX has an Altman Z-Score of 2.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.22 |
| Piotroski F-Score | 4 |